Company: GVH
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001493152-25-006117
Chunk: 62

Company: Globavend Holdings Ltd
Filing Date: 2025-02-12
Form: 20-F
Item: Item 3
Chunk 62
---
 on
the market price of the ELOC Shares.

  34  

  Table of Contents  

Any issuance and
sale by us under the ELOC Purchase Agreement of a substantial amount of ELOC Shares could cause substantial dilution to our shareholders.
The number of ELOC Shares ultimately offered for sale by the Investor is dependent upon the number of ELOC Shares, if any, we ultimately
elect to sell to the Investor under the ELOC Purchase Agreement. However, even if we elect to sell ELOC Shares to the Investor pursuant
to the ELOC Purchase Agreement, the Investor may resell all, some or none of such shares at any time or from time to time in its sole
discretion and at different prices.

It is not possible to predict the
actual number of ELOC Shares, if any, we will sell under the ELOC Purchase Agreement to the Investor, or the actual gross proceeds resulting
from those sales.

Pursuant to the ELOC
Purchase Agreement, we will have discretion, to vary the timing, price and number of shares sold to the Investor. If and when we elect
to sell the ELOC Shares to the Investor pursuant to the ELOC Purchase Agreement, after the Investor has acquired such ELOC Shares, the
Investor may resell all, some or none of such shares at any time or from time to time in its sole discretion and at different prices.
As a result, investors who purchase shares from the Investor in this offering at different times will likely pay different prices for
those shares, and so may experience different levels of dilution and in some cases substantial dilution and different outcomes in their
investment results. Investors may experience a decline in the value of the shares they purchase from the Investor in this offering as
a result of future sales made by us to Investor at prices lower than the prices such investors paid for their shares in this offering.
In addition, if we sell a substantial number of shares to the Investor under the ELOC Purchase Agreement, or if investors expect that
we will do so, the actual sales of shares or the mere existence of our arrangement with the Investor may make it more difficult for us
to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales.

The sale of a substantial amount
of ELOC Shares in the public market could adversely affect the prevailing market price of our Ordinary Shares.

We have registered
for resale an aggregate of up to $20 million of ELOC Shares,